NovaDel Pharma to Present at Equities Magazine Discovery Day XI
Conference Today
FLEMINGTON, N.J., Sept. 15 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. (AMEX:NVD), a leading formulator of lingual spray drugs for systemic delivery
through the oral mucosa, said Gary A. Shangold, MD, president and chief
executive officer, and Barry Cohen, vice president of new business and product
development, will present at the Equities Magazine Discovery Day XI Conference
in New York today, September 15th, at 1:00 pm EST.
Dr. Shangold and Mr. Cohen will review the company's plans and operations
during the current year.
A webcast of the presentation will be available; to access it, please use the
direct link to the webcast at: http://www.vcall.com/CEPage.asp?ID=89137 .
About NovaDel Pharma, Inc.
NovaDel Pharma, Inc. is a specialty pharmaceutical company engaged in the
development of novel drug delivery systems for prescription and
over-the-counter drugs. The company's proprietary lingual spray technology
delivery system offers the patient (i) fast onset of action; (ii) improved drug
safety by reducing the required drug dosage and reducing side effects; (iii)
improved patient convenience and compliance; and (iv) enhanced dosage
reliability. The company plans to develop such products independently and
through collaborative arrangements with major pharmaceutical and biotech
companies.
Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve known and unknown risks
and uncertainties that may cause the Company's actual results or outcomes to be
materially different from those anticipated and discussed herein including, but
not limited to, the ability to develop products (independently and through
collaborative arrangements), and the ability to commercialize and obtain
approval for products under development. Further, the Company operates in
industries where securities may be volatile and may be influenced by regulatory
and other factors beyond the Company's control. Important factors that the
Company believes might cause such differences are discussed in the risk factors
detailed in the Company's most recent Annual Report and Registration
Statements, filed with the Securities and Exchange Commission. In assessing
forward-looking statements contained herein, if any, the reader is urged to
carefully read all cautionary statements contained in such filings.
CONTACT:
Thomas Redington
212 926-1733
DATASOURCE: NovaDel Pharma, Inc.
CONTACT: Thomas Redington for NovaDel Pharma, +1-212-926-1733 Web site: http://www.vcall.com/CEPage.asp?ID=89137
|